公开(公告)号：EP2579901B1

公开(公告)日：2019-08-07

申请号：EP11793174.1

申请日：2011-06-09

Applicant: The Board of Trustees of The University of Arkansas

Inventor： HARGIS, Billy ,  PUMFORD, Neil, R. ,  KWON, Young, Min ,  LAYTON, Sherryll

IPC: A61K39/02 ,  C07K14/205

公开(公告)号：EP2411503B1

公开(公告)日：2017-09-13

申请号：EP10715098.9

申请日：2010-03-25

Applicant: Eidgenössische Technische Hochschule Zürich

Inventor： ILG, Karin ,  AEBI, Markus ,  AHUJA, Umesh ,  AMBER, Saba ,  SCHWARZ, Flavio

IPC: C12N1/20 ,  C12N1/36 ,  C07K14/205 ,  A61K39/106 ,  A61K39/112

CPC classification number: A61K39/105 ,  A61K39/0275 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/542 ,  A61K2039/55 ,  A61K2039/552 ,  C12N1/20 ,  C12N1/36 ,  Y02A50/47 ,  Y02A50/482

Abstract: The present invention relates to Salmonella enterica comprising at least one pgl operon of Campylobacter jejuni or a functional derivative thereof and presenting at least one N-glycan of Campylobacter jejuni or N-glycan derivative thereof on its cell surface. In addition, it is directed to medical uses and pharmaceutical compositions thereof as well as methods for treating and/or preventing Campylobacter and optionally Salmonella infections and methods for producing these Salmonella strains.

Abstract translation: 本发明涉及包含至少一种空肠弯曲杆菌的pgI操纵子或其功能性衍生物并且在其细胞表面上呈递至少一种空肠弯曲菌或其N-聚糖衍生物的肠沙门氏菌。 此外，其涉及医学用途和其药物组合物以及治疗和/或预防弯曲杆菌和任选的沙门氏菌感染的方法以及用于生产这些沙门氏菌菌株的方法。

公开(公告)号：EP2280991B1

公开(公告)日：2016-06-22

申请号：EP09732473.5

申请日：2009-04-17

Applicant: VaxInnate Corporation

Inventor： SONG, Langzhou ,  TUSSEY, Lynda, G. ,  SHAW, Alan, R. ,  BECKER, Robert, S. ,  ZHANG, Yi ,  UMLAUF, Scott, W. ,  TAYLOR, David, N. ,  LIU, Ge ,  YEAGER, Mark, D. ,  POWELL, Thomas, J.

IPC: C07K14/255 ,  A61K39/00 ,  A61K39/112 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/295 ,  A61K39/39 ,  C07K14/005 ,  C07K14/11 ,  C07K14/205 ,  C07K14/21 ,  C07K14/24 ,  C07K14/245 ,  C07K14/32 ,  C07K19/00 ,  C12N7/00

CPC classification number: A61K39/39 ,  A61K9/127 ,  A61K9/5153 ,  A61K39/00 ,  A61K39/0005 ,  A61K39/0275 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/295 ,  A61K47/6937 ,  A61K2039/55516 ,  A61K2039/55544 ,  A61K2039/55555 ,  A61K2039/6031 ,  A61K2039/6068 ,  C07K14/005 ,  C07K14/11 ,  C07K14/205 ,  C07K14/21 ,  C07K14/24 ,  C07K14/245 ,  C07K14/255 ,  C07K14/32 ,  C07K19/00 ,  C07K2319/40 ,  C07K2319/75 ,  C12N7/00 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2710/20071 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16162 ,  C12N2760/16171 ,  C12N2760/16222 ,  C12N2760/16234 ,  C12N2760/16271 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24171 ,  Y02A50/386 ,  Y02A50/394 ,  Y02A50/412

Abstract: Compositions that include Toll-like Receptor 5 agonists and at least a portion of at least one influenza antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection.

公开(公告)号：EP2224012B1

公开(公告)日：2013-01-30

申请号：EP10163178.6

申请日：2002-12-16

Applicant: CORIXA CORPORATION

Inventor： Hershberg, Robert M. ,  Hosken, Nancy Ann ,  Lodes, Michael J. ,  Mohamath, Raodoh

IPC: C07K14/195 ,  C07K14/205 ,  G01N33/68 ,  G01N33/50

CPC classification number: C07K16/1232 ,  A61K38/00 ,  A61K39/00 ,  A61K39/40 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/523 ,  A61K2039/53 ,  C07K14/001 ,  C07K14/195 ,  C07K14/205 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/00 ,  G01N33/505 ,  G01N33/6893 ,  G01N2800/065

公开(公告)号：EP2310405A1

公开(公告)日：2011-04-20

申请号：EP09793719.7

申请日：2009-07-13

Applicant: Phylogica Limited

Inventor： WATT, Paul Michael ,  HOPKINS, Richard

IPC: C07K14/195 ,  A61K38/10 ,  A61P7/04 ,  A61P31/12 ,  A61P35/00 ,  A61P37/00 ,  C07K7/08 ,  C07K14/205 ,  C07K14/21 ,  C07K14/215 ,  C07K14/22 ,  C07K14/235 ,  C07K14/245 ,  C07K14/255 ,  C07K14/32 ,  A61K38/16

CPC classification number: C07K14/195 ,  A61K38/00 ,  C07K7/08

Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signaling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.

Abstract translation: 本发明提供了包含CD40L依赖性信号肽的肽基抑制剂的组合物，其不是来源于CD40L的天然结合配偶体如CD40或来自天然CD40-CD40L接口。 更特别地，本发明的肽基抑制剂来源于不表达CD40-CD40L共刺激途径的天然来源。 本发明还提供了肽基抑制剂的合成衍生物和类似物，其相对于其亲代分子具有增强的对CD40L的结合亲和力或增强的抑制活性。

公开(公告)号：EP1586646B1

公开(公告)日：2011-03-09

申请号：EP05104073.1

申请日：2001-12-14

Applicant: Intervet International BV

Inventor： Jacobs, Antonius Arnoldus Christiaan ,  Vermeij, Paul

IPC: C12N15/31 ,  C12N1/21 ,  C12Q1/68 ,  C07K14/195 ,  C07K14/205 ,  A61K39/02 ,  A61K39/40 ,  G01N33/569

CPC classification number: C07K14/205 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  C07K14/195

公开(公告)号：EP1871884A2

公开(公告)日：2008-01-02

申请号：EP06740938.3

申请日：2006-04-13

Applicant: Merial Ltd.

Inventor： ELLIS, JOHN ,  CHARREYRE, Catherine ,  MARTINON, Olivier, Michel

IPC: C12N15/34 ,  C07K14/01 ,  C07K14/205 ,  A61K39/295

CPC classification number: A61K39/12 ,  A61K39/00 ,  A61K39/105 ,  A61K2039/521 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/70 ,  C07K14/005 ,  C07K16/081 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24043 ,  C12N2750/10021 ,  C12N2750/10034 ,  C12N2750/10043

Abstract: The present invention is based on the discovery of novel species of the genus Helicobacter that are associated with gastroesophageal ulceration in pigs. In particular, a novel species, H. cerdo, has been used as a source of antigenic material for the development of vaccine for the treatment of the gastroesophageal disorders. Most advantageously, the novel Helicobacter and the porcine circoviruses associated with PMWS in pigs are useful for providing combination vaccines whereby immunogens derived from both types of pathogens may be codelivered to the tax get animal to stimulate the generation of protective antibodies and immunity. The invention, therefore, provides vaccines that are useful for the tratment of gastro esophageal ulceration and PMWS in porcines. The present invention includes, therefore, multivalent immunogenic compositions and vaccines, multivaccine kits, and combined immunization or vaccination methods which make it possible to use such combined immunization or vaccination programmes.

公开(公告)号：EP1837345A1

公开(公告)日：2007-09-26

申请号：EP06006041.5

申请日：2006-03-23

Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. ,  Universität Hamburg

Inventor： Wunder, Christian ,  Churin, Yuri ,  Meyer, Thomas F. ,  Warnecke, Dirk, Dr. ,  Lebrun, Anne-Hélène ,  Hildebrand, Janosch

IPC: C07K14/205 ,  C12N9/10 ,  A61K38/00

CPC classification number: C07K14/205 ,  A61K38/00 ,  C12N9/1051

Abstract: The present invention refers to pharmaceutical compositions comprising cholesteryl-α-glucosyltransferase from Helicobacter, inhibitors of cholesteryl-α-glucosyltransferase and the use thereof for the manufacture of a medicament for the prevention or/and treatment of Helicobacter infection or/and a Helicobacter -associated disease. Another subject is the screening method for novel inhibitors of cholesteryl-α-glucosyltransferase.

Abstract translation: 本发明涉及药物组合物源自螺杆菌包括胆固醇±葡糖基转移酶，胆甾醇抑制剂±葡糖基转移酶和它们用于螺杆菌感染和/或螺杆菌的预防和/或治疗的药物的制造中的用途 - 相关 疾病。 另一主题是用于胆固醇±葡糖基转移酶的新型抑制剂的筛选方法。

公开(公告)号：EP0909272B1

公开(公告)日：2007-02-07

申请号：EP97927563.3

申请日：1997-06-10

Applicant: Borén, Thomas

Inventor： BOREN, Thomas ,  ARNQVIST, Anna ,  NORMARK, Staffan ,  ILVER, Dag ,  HAMMARSTRÖM, Lennart, Huddinge Sjukhus

IPC: C07K14/205 ,  A61K39/106 ,  C07K16/12

CPC classification number: C07K14/205 ,  A61K39/00 ,  A61K2039/51

Abstract: A novel Helicobacter pylori blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to fucosylated blood group antigens. The protein sequence of said adhesin is disclosed in this application. Simultaneously the DNA sequences for two genes, babA and babB, producing highly similar proteins, are disclosed. Said adhesin and/or DNA is useful for diagnose and therapy and/or prophylaxis directed against H. pylori induced infections, e.g. gastritis and acid peptic disease, i.e. active vaccination. A new immunoglobulin composition, which exhibits specific activity to a Lewis antigen binding Helicobacter pylori adhesin, or preferably, monoclonal and/or polyclonal antibodies to said adhesin offer a new and more efficient method of treatment and/or prevention of gastrointestinal diseases, caused by Helicobacter pylori or other Helicobacter species, i.e. passive vaccination.

公开(公告)号：EP0973394A4

公开(公告)日：2005-03-30

申请号：EP97913847

申请日：1997-10-28

Applicant: ASTRAZENECA AB

Inventor： SMITH DOUGLAS ,  ALM RICHARD A

IPC: C12N15/09 ,  A61K31/711 ,  A61K39/00 ,  A61K39/106 ,  A61K48/00 ,  A61P31/04 ,  C07K14/195 ,  C07K14/205 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/31 ,  C12N15/86 ,  C12P21/02 ,  C12Q1/68 ,  C07K19/00 ,  C12N15/63 ,  G01N33/68

CPC classification number: C07K14/205 ,  A61K39/00 ,  C07K2319/00

Abstract: Recombinant or substantially pure preparations of H. pylori polypeptides are described. The nucleic acids encoding the polypeptides also are described. The H. pylori polypeptides are useful for diagnostics and vaccine compositions.

Abstract translation: 幽门螺杆菌多肽的重组或基本上纯的制剂进行了描述。 这样描述编码多肽的核酸。 该幽门螺杆菌多肽是用于诊断和疫苗组合物。